Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vifor Pharma Group

http://www.viforpharma.com/

Latest From Vifor Pharma Group

Keeping Track: US FDA Clears Vaxneuvance, Rezurock And Karendia, But Not Teplizumab

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Bayer Focusing On Early CKD Testing In Kerendia US Launch

The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.

Launches Renal

Vifor Drops CV Endpoints In Phase IIIb Veltassa Study After COVID-19 Impacts

Vifor Pharma is still hoping for further clinical data to help differentiate its potassium binder Veltassa in the competitive hyperkalemia market after recruitment into its Phase IIIb DIAMOND study was slowed by COVID-19-related changes to clinical practice, necessitating a new primary endpoint.

AgomAb Therapeutics Identifies Regenerative Pathway Modulators, Attracts Investors

Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.

Regenerative Medicine Inflammation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
    • Galenica Group
    • Relypsa, Inc.
    • Vifor Pharma
    • Vifor-Fresenius Medical Care Renal Pharma Ltd.
    • OM Pharma
UsernamePublicRestriction

Register